Simvastatin improves final visual outcome in acute optic neuritis: A randomized study

Multiple Sclerosis Journal

Volumn 18, Issue 1, 2012, Pages 72-81

  Tsakiri, Anna ^a   Kallenbach, Klaus ^a   Fuglø, Dan ^b   Wanscher, Benedikte ^b   Larsson, Henrik ^b   Frederiksen, Jette ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

disease modifying therapies; multiple sclerosis

Indexed keywords

GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ACUTE DISEASE; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COLOR VISION; CONTRAST ENHANCEMENT; CONTRAST SENSITIVITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVOKED VISUAL RESPONSE; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OPTIC NEURITIS; OVARY CYST; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VISUAL ACUITY; VISUAL ANALOG SCALE; WHOLE BODY MRI;

EID: 84855945971     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511415452     Document Type: Article

References (40)

1. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005 ; 4: 111-121 (Pubitemid 40138926)
2. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology. 1997 ; 49: 1404-1413
3. Germann CA, Baumann MR, Hamzavi S. Ophthalmic diagnoses in the ED: Optic neuritis. Am J Emerg Med. 2007 ; 25: 834-837 (Pubitemid 47385051)
4. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002 ; 360: 1953-1962 (Pubitemid 35472140)
5. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001 ; 187: 81-89 (Pubitemid 32611661)
6. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: Comparison with interferon-beta 1b in MS. Neurology. 2002 ; 59: 990-997
7. Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis?. Lancet Neurol. 2004 ; 3: 369-371 (Pubitemid 38648858)
8. Sena A, Pedrosa R, Graca MM. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol. 2003 ; 250: 754-755 (Pubitemid 36718367)
9. Stuve O, Prod'homme T, Youssef S, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep. 2004 ; 4: 237-244 (Pubitemid 38899077)
10. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004 ; 363: 1607-1608 (Pubitemid 38625664)
11. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: A pluripotent family of agents with several potential applications. Curr Pharm Des. 2007 ; 13: 3622-3636 (Pubitemid 350238933)
12. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003 ; 197: 725-733 (Pubitemid 36350867)
13. Weber MS, Steinman L, Zamvil SS. Statins-treatment option for central nervous system autoimmune disease?. Neurotherapeutics. 2007 ; 4: 693-700 (Pubitemid 47499293)
14. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994 ; 36 (1). S73 - S79
15. Lanthony P. The desaturated panel D-15. Doc Ophthalmol. 1978 ; 46: 185-189 (Pubitemid 9043296)
16. Mäntyjärvi M. Velhagen Pfügertrident pseudoisochromatic plates in screening congenital red-green vision defects. Graefes Arch Clin Exp Ophthalmol. 1991 ; 229: 145-146
17. Halliday AM. Visual evoked potentials. Bull Soc Belge Ophtalmol. 1983 ; 208: 323-331
18. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: Treatment and trust. Drugs. 2001 ; 61: 197-206 (Pubitemid 32210196)
19. Illingworth DR, Crouse JR, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001 ; 17: 43-50 (Pubitemid 32594972)
20. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999 ; 52: 1479-1484 (Pubitemid 29190544)
21. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005 ; 64: 804-810 (Pubitemid 40316316)
22. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992 ; 326: 581-588
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846 (Pubitemid 41746873)
24. Jones SJ, Brusa A. Neurophysiological evidence for long-term repair of MS lesions: Implications for axon protection. J Neurol Sci. 2003 ; 206: 193-198 (Pubitemid 36143727)
25. Halliday AM. Visual evoked potentials in demyelinating disease. Adv Neurol. 1981 ; 31: 201-215
26. Frederiksen JL, Petrera J, Larsson HB, Stigsby B, Olesen J, Serial MRI. VEP, SEP and biotesiometry in acute optic neuritis: Value of baseline results to predict the development of new lesions at one year follow up. Acta Neurol Scand. 1996 ; 93: 246-252 (Pubitemid 26155202)
27. Frederiksen JL, Sorensen TL, Sellebjerg FT. Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up. Acta Ophthalmol Scand. 1997 ; 75: 544-547 (Pubitemid 28022346)
28. Frederiksen JL, Petrera J. Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol. 1999 ; 44 (1). S54 - S62
29. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996 ; 121: 547-553 (Pubitemid 26135863)
30. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001 ; 56: 1514-1522 (Pubitemid 32532263)
31. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials. J Neurol. 2000 ; 247: 435-442 (Pubitemid 30433557)
32. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999 ; 52: 1479-1484 (Pubitemid 29190544)
33. Salvatore E, Morra VB, Orefice G. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2009 ; 73 (13). 1078-1079
34. May Thomas S., Laurie Barclay MD.. Simvastatin Does Not Antagonize Interferon-Beta, Interim Analysis Suggests. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis: Parallel Session 7 (85) ; ;..
35. Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: A double-blind randomized controlled trial. Mult Scler. 2010 ; 16: 848-854
36. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003 ; 197: 725-733 (Pubitemid 36350867)
37. Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett. 1999 ; 269: 71-74 (Pubitemid 29335415)
38. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 ; 420: 78-84 (Pubitemid 35291443)
39. Paintlia AS, Paintlia MK, Singh AK, et al. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res. 2004 ; 77: 63-81 (Pubitemid 38850056)
40. Wattjes MP, Harzheim M, Kuhl CK, et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?. AJNR Am J Neuroradiol. 2006 ; 27: 1794-1798 (Pubitemid 44413574)